Pamela J. McShane

This study evaluates sulbactam-durlobactam plus ceftriaxone dosing and combination regimens for Mycobacterium abscessus lung disease, finding that sulbactam-durlobactam-ceftriaxone achieves the highest microbial kill in a hollow fiber model.

The paper evaluates new drug regimens for Mycobacterium avium lung disease using an in vitro model and basis functions, finding that ceftriaxone-omadacycline-rifabutin outperforms the standard-of-care.